Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Notably, cholecalciferol (vitamin D3), nicotinamide (a precursor of NAD⁺), sparstolonin B (a plant‐derived antioxidant and anti‐inflammatory compound), and all‐trans‐retinoic acid (a key regulator of neuronal differentiation and survival) were all significantly increased in metformin‐treated organoids.

Source: Metabolic Changes in POLG Patient‐Derived Cortical Organoids with Metformin Treatment. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Research setting awaiting verification

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Metformin Restores Mitochondrial Function and Neurogenesis in POLG Patient‐Derived Brain Organoids

Study design awaiting verification · Advanced Science · 2025

Original publication title

Metformin Restores Mitochondrial Function and Neurogenesis in POLG Patient‐Derived Brain Organoids

Zhuoyuan Zhang; Tsering Yangzom; Ning Lu; Shenglong Deng; Xianglu Xiao; Guang Yang; Kristina Xiao Liang

© 2025 The Author(s). Advanced Science published by Wiley‐VCH GmbH

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

What does the authors’ abstract report?

Abstract

Mitochondrial dysfunction and impaired neurogenesis are central to mitochondrial DNA polymerase (POLG)‐related disorders, yet therapeutic options remain limited. Here, patient‐derived induced pluripotent stem cell (iPSC)‐based cortical organoids are used to model POLG‐associated neurodegeneration and assess the therapeutic potential of metformin. Single‐cell RNA‐seq reveals distinct vulnerabilities in dopaminergic, glutamatergic, and GABAergic neuronal subtypes, with dopaminergic neurons exhibiting the most severe loss and mitochondrial transcriptomic deficits. Metformin treatment (250 µm, 2 months) significantly restores neuronal identity, subtype‐specific gene expression, and mitochondrial function.

Functional assays demonstrate improved mitochondrial membrane potential (TMRE), increased mitochondrial mass (MTG, MTDR), and reduced oxidative stress (MitoSOX, BAX/cleaved caspase 3). Notably, mitochondrial DNA (mtDNA) copy number and the expression of mitochondrial replisome proteins (POLG, POLG2) are upregulated, indicating enhanced mitochondrial genome maintenance. Calcium measurement confirms improved neuronal excitability. Untargeted metabolomics further reveals metformin‐induced metabolic reprogramming, including enrichment of the tricarboxylic acid (TCA) cycle, amino acid metabolism, and redox‐related pathways. Together, these findings demonstrate that metformin enhances mitochondrial integrity and neural function across multiple neuronal subtypes and offer mechanistic insights into its potential as a treatment for POLG‐related disorders.

Authors’ abstract

Abstract

Mitochondrial dysfunction and impaired neurogenesis are central to mitochondrial DNA polymerase (POLG)‐related disorders, yet therapeutic options remain limited. Here, patient‐derived induced pluripotent stem cell (iPSC)‐based cortical organoids are used to model POLG‐associated neurodegeneration and assess the therapeutic potential of metformin. Single‐cell RNA‐seq reveals distinct vulnerabilities in dopaminergic, glutamatergic, and GABAergic neuronal subtypes, with dopaminergic neurons exhibiting the most severe loss and mitochondrial transcriptomic deficits. Metformin treatment (250 µm, 2 months) significantly restores neuronal identity, subtype‐specific gene expression, and mitochondrial function.

Functional assays demonstrate improved mitochondrial membrane potential (TMRE), increased mitochondrial mass (MTG, MTDR), and reduced oxidative stress (MitoSOX, BAX/cleaved caspase 3). Notably, mitochondrial DNA (mtDNA) copy number and the expression of mitochondrial replisome proteins (POLG, POLG2) are upregulated, indicating enhanced mitochondrial genome maintenance. Calcium measurement confirms improved neuronal excitability. Untargeted metabolomics further reveals metformin‐induced metabolic reprogramming, including enrichment of the tricarboxylic acid (TCA) cycle, amino acid metabolism, and redox‐related pathways. Together, these findings demonstrate that metformin enhances mitochondrial integrity and neural function across multiple neuronal subtypes and offer mechanistic insights into its potential as a treatment for POLG‐related disorders.

Publication and source details

Original title: Metformin Restores Mitochondrial Function and Neurogenesis in POLG Patient‐Derived Brain Organoids

Zhuoyuan Zhang; Tsering Yangzom; Ning Lu; Shenglong Deng; Xianglu Xiao; Guang Yang; Kristina Xiao Liang

Advanced Science · 2025

* E‐mail: xiao.liang@uib.no
© 2025 The Author(s). Advanced Science published by Wiley‐VCH GmbHhttps://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. University of Bergen Meltzers Høyskolefonds 103517133 Gerda Meyer Nyquist Legat 103816102 POLG Foundation 104291 ERC IMI 101005122 MRC10.13039/501100000265 MC/PC/21013 Royal Society10.13039/501100000288 IEC∖NSFC∖211235 NVIDIA Academic Hardware Grant Program Boehringer Ingelheim Ltd UKRI Future Leaders Fellowship MR/V023799/1 H202010.13039/100010661 952172 NIHR Imperial Biomedical Research Centre10.13039/501100013342 RDA01 Swiss National Science Foundation10.13039/501100001711 220785 Temasek Trust UKRI guarantee funding for Horizon Europe MSCA Postdoctoral Fellowships EP/Z002206/1 UKRI MRC Research Grant TFS Research Grants MR/U506710/1

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T01:15:44.604042+00:00

DOI: 10.1002/advs.202417721 · PMC12822396